Table 1.
Treatment/assay | AO/EB/H (%) |
PI−/DiOC6(3)+
(%) |
---|---|---|
Untreated | 1 ± 0** | 98 ± 1** |
ROT (50 μM) | 50 ± 3** | 51 ± 2** |
PDTC (10 nM) | 1 ± 0** | 97 ± 1** |
PDTC (10 nM) + ROT (50 μM) | 9 ± 3** | 89 ± 3** |
PFT (50 nM) | 1 ± 0** | 98 ± 1** |
PFT (50 nM) + ROT (50 μM) | 11 ± 2** | 87 ± 3** |
SP600125 (1 μM) | 2 ± 1** | 97 ± 1** |
SP600125 (1 μM) + ROT (50 μM) | 6 ± 2** | 93 ± 3** |
NSCI (10 μM) | 1 ± 0** | 98 ± 1** |
NSCI (10 μM) + ROT (50 μM) | 5 ± 1** | 94 ± 2** |
NAC (1 mM) | 1 ± 0** | 98 ± 1** |
NAC (1 mM) + ROT (50 μM) | 10 ± 3** | 89 ± 1** |
Jurkat cells (1 × 106 cells/mL) were exposed to ROT (50 μM) in absence or presence of PDTC (10 nM), pifithrin-α (PFT, 50 nM), SP600125 (1 μM) and NSCI (10 μM) signaling inhibitors, and NAC (1 mM) at 37°C for 24 h. Cells were then evaluated for apoptotic nuclei morphology and mitochondrial membrane potential, as described in Material and Methods. The percentage of positive AO/EB/Hoechst staining and PI−/DiOC6(3)+ of Jurkat cells treated with or without ROT is expressed as a mean percentage ± S.D. from three independent experiments. **P < 0.001.